Effects of treatment with a commercially available St John's Wort product (Movina®) on cholesterol levels in patients with hypercholesterolemia treated with simvastatin

Scandinavian Journal of Primary Health Care

Volumn 25, Issue 3, 2007, Pages 154-159

  Eggertsen, Robert ^a,c   Andreasson, Åke ^b   Andrén, Lennart ^b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c Mölnlycke Vårdcentral ^*  (Sweden)

Author keywords

Hypercholesterolemia; Hypericum perforatum; Interactions; LDL cholesterol; Simvastatin; St John's Wort

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPERICUM PERFORATUM EXTRACT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MOVINA; MULTIVITAMIN; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; HERB DRUG INTERACTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERICUM PERFORATUM; MALE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERICUM; MALE; MIDDLE AGED; PHYTOTHERAPY; PLANT PREPARATIONS; SIMVASTATIN; TABLETS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 34548609183     PISSN: 02813432     EISSN: 15027724     Source Type: Journal    
DOI: 10.1080/02813430701442768     Document Type: Article

References (28)

1. Thomas KJ, Nicholl JP, Coleman P. Use and expenditure on complementary medicine in England: A population based survey. Complement Ther Med 2001;9:2-11.
2. Hanssen B, Grimsgaard S, Launsö L, Fönnebo V, Falkenberg T, Rasmussen NK. Use of complimentary and alternative medicine in the Scandinavian countries. Scand J Prim Health Care 2005;23:57-62.
3. Stjernberg L, Berglund J, Halling A. Age and gender on the use of herbal medicine products and food supplements among the elderly. Scand J Prim Health Care 2006;24:50-5.
4. Mills E, Montori VM, Wu P, Gallicano K, Clarke M, Guyatt G. Interaction of St John's wort with conventional drugs: systematic review of clinical trials. BMJ 2004;329:27-30.
5. Johne A, Schmider J, Brockmoller J, Stadelmann AM, Stormer E, Bauer S, et al. Decreased plasma levels of amitriptyline and its metabolites on co-medication with an extract from St John's Wort (Hypericum perforatum). J Clin Psychopharmacol 2002;22:46-54.
6. Piscitteli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations and St John's Wort. Lancet 2000;355:547-8.
7. Ruschizka F, Meier PJ, Turina M, Luscher TF, Noll G. Acute heart transplant rejection due to Saint John's Wort. Lancet 2000;355:548-9.
8. Pharmacy information in Western Sweden (LUPP, Läkemedelsupplysningen i Västra Sverige, lupp.su@vgregion.se).
9. Shelton RC, Keller MB, Gelenberg A, Dunner DL, et al. Effectiveness of St John's Wort in major depression: A randomized controlled trial. JAMA 2001;285:1978-86.
10. Szegedi AS, Kohnen R, Dienel A, Kieser M. Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's Wort): Eandomised controlled double-blind non-inferiority trial versus paroxetine. BMJ 2005;330:503-6.
11. Durr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert H, Meier PJ, Fattinger K. St John's Wort induces intestinal P-glucoprotein/MDR1 and intestinal and hepatic CYP 3A4. Clin Pharmacol Therapeut 2000;68:598-604.
12. Markowitz JS, Donovan JL, DeVane CL, Taylor RM, Ruan Y, Wang JS, Chavin KD. Effects of St John's Wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 2003;290:1500-4.
13. Vickers S, Duncan CA, Chen IW, Rosegay A, Duggan DE. Metabolic disposition studies of simvastatin, a cholesterol-lowering prodrug. Drug Metab Dispos 1990;18:138-45.
14. Christians U, Jacobsen W, Floren LC. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: Are the statins mechanistically similar? Pharmacol Ther 1998;80:1-34.
15. Sugimoto KI, Ohmori M, Tsuruoka S, Nishiki K, et al. Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin. Pharmacol therapeut 2001;70:518-24.
16. Medical Products Agency. http://www.lakemedelsverket.se
17. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 1994;344:1383-8.
18. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998;97:1440-5.
19. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-52.
20. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16.
21. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL Study: A randomized controlled trial. JAMA 2001;285:1711-8.
22. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549-59.
23. Förebyggande av aterosklerotisk hjärt-kärlsjukdom (Prevention of atherosclerotic cardiovascular disease). Information from Läkemedelsverket 2006;17:16-97.
24. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, et al. for the REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on prognosis of coronary atherosclerosis: A randomized controlled trial. JAMA 2004;291:1071-80.
25. LaRosa JC, Grundy SM, Waters DD, Shear C, et al. for the Treating to New Target (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35.
26. Major outcomes in moderately hypercholesterolemic hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002;288:2998-3007.
27. Sever PS, Dahlöf B, Poulter NR, Wedel H, et.al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial. The Lipid Lowering Arm (ASCOTLLA): A multicenter randomized controlled trial. Drugs 2004;64:43-60.
28. Jones P, Kafonek S, Laurora IL. Hunninghake D for the CURVES investigators. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (The Curves Study). Am J Cardiol 1998;81:582-7.